Kyowa Kirin
Kyowa Hakko Kirin engages in the manufacture and sale of medical products and pharmaceuticals.
Launch date
Employees
Market cap
€12.0b
Enterprise valuation
€9.8b (Public information from Sep 2024)
Share price
JPY3199 4151.T
Tokyo Japan (HQ)
Financials
Estimates*
JPY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 318.4b | 352.2b | 398.4b | 442.2b | 488.9b | 499.1b | 523.4b |
% growth | 4 % | 11 % | 13 % | 11 % | 11 % | 2 % | 5 % |
EBITDA | 73.0b | 80.7b | 87.1b | 118.5b | 115.5b | 122.1b | 135.8b |
% EBITDA margin | 23 % | 23 % | 22 % | 27 % | 24 % | 24 % | 26 % |
Profit | 47.0b | 52.3b | 53.6b | 81.2b | 68.2b | 73.9b | 81.8b |
% profit margin | 15 % | 15 % | 13 % | 18 % | 14 % | 15 % | 16 % |
EV / revenue | 3.9x | 3.8x | 3.2x | 2.0x | 2.9x | 2.8x | 2.6x |
EV / EBITDA | 16.8x | 16.7x | 14.7x | 7.3x | 12.3x | 11.3x | 9.9x |
R&D budget | 52.3b | 57.7b | 62.9b | 72.1b | - | - | - |
R&D % of revenue | 16 % | 16 % | 16 % | 16 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | N/A | IPO | |
Total Funding | - |
Recent News about Kyowa Kirin
EditACQUISITION by Novo Nordisk Nov 2021
ACQUISITION by Kyowa Kirin Oct 2023